Ken Griffin Amicus Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,700 shares of FOLD stock, worth $258,567. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,700

Previous 24,700 4.05%

Holding current value

$258,567

Previous $290,000 18.97%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$9.04 - $11.75 $15.1 Million - $19.6 Million	1,665,714 Added 123.28%	3,016,896 $29.9 Million
Q1 2024 May 15, 2024	BUY	$11.43 - $14.24 $15 Million - $18.6 Million	1,308,411 Added 3059.11%	1,351,182 $15.9 Million
Q4 2023 Feb 14, 2024	BUY	$9.97 - $14.52 $63,957 - $93,145	6,415 Added 17.64%	42,771 $606,000
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $371,741 - $437,380	31,557 Added 657.57%	36,356 $442,000
Q2 2023 Aug 14, 2023	SELL	$10.72 - $13.3 $5.35 Million - $6.64 Million	-499,177 Reduced 99.05%	4,799 $60,000
Q1 2023 May 15, 2023	BUY	$10.91 - $13.54 $4.11 Million - $5.1 Million	376,877 Added 296.52%	503,976 $5.59 Million
Q4 2022 Feb 14, 2023	SELL	$9.89 - $12.7 $16.8 Million - $21.6 Million	-1,701,360 Reduced 93.05%	127,099 $1.55 Million
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $18.6 Million - $24.2 Million	-1,899,081 Reduced 50.95%	1,828,459 $19.1 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $11.12 $13.6 Million - $24.3 Million	2,185,467 Added 141.72%	3,727,540 $40 Million
Q1 2022 May 16, 2022	SELL	$7.89 - $12.48 $217,992 - $344,809	-27,629 Reduced 1.76%	1,542,073 $14.6 Million
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $12.8 Million - $16.2 Million	-1,304,692 Reduced 45.39%	1,569,702 $18.1 Million
Q3 2021 Nov 15, 2021	BUY	$8.74 - $11.84 $13.1 Million - $17.8 Million	1,501,395 Added 109.35%	2,874,394 $27.5 Million
Q2 2021 Aug 16, 2021	BUY	$8.71 - $10.72 $7.69 Million - $9.46 Million	882,896 Added 180.14%	1,372,999 $13.2 Million
Q1 2021 May 17, 2021	BUY	$9.2 - $23.86 $1.14 Million - $2.96 Million	123,920 Added 33.84%	490,103 $4.84 Million
Q4 2020 Feb 16, 2021	SELL	$13.47 - $24.89 $7.23 Million - $13.4 Million	-536,548 Reduced 59.44%	366,183 $8.46 Million
Q3 2020 Nov 16, 2020	SELL	$12.89 - $15.89 $11.5 Million - $14.2 Million	-893,270 Reduced 49.74%	902,731 $12.7 Million
Q2 2020 Aug 14, 2020	SELL	$8.86 - $15.69 $2.48 Million - $4.38 Million	-279,427 Reduced 13.46%	1,796,001 $27.1 Million
Q1 2020 May 15, 2020	SELL	$6.63 - $11.16 $11.9 Million - $20.1 Million	-1,797,071 Reduced 46.41%	2,075,428 $19.2 Million
Q4 2019 Feb 14, 2020	SELL	$7.48 - $10.75 $6.84 Million - $9.83 Million	-914,428 Reduced 19.1%	3,872,499 $37.7 Million
Q3 2019 Nov 14, 2019	SELL	$8.02 - $13.25 $68,827 - $113,711	-8,582 Reduced 0.18%	4,786,927 $38.4 Million
Q2 2019 Aug 14, 2019	SELL	$10.96 - $14.4 $18 Million - $23.6 Million	-1,638,905 Reduced 25.47%	4,795,509 $59.8 Million
Q1 2019 May 15, 2019	BUY	$10.04 - $13.92 $55.9 Million - $77.4 Million	5,562,878 Added 638.28%	6,434,414 $0
Q4 2018 Feb 14, 2019	BUY	$8.38 - $13.44 $6.06 Million - $9.72 Million	722,864 Added 486.21%	871,536 $8.35 Million
Q3 2018 Nov 13, 2018	SELL	$11.6 - $16.54 $2.85 Million - $4.06 Million	-245,497 Reduced 62.28%	148,672 $0
Q1 2018 May 11, 2018	SELL	$13.76 - $17.12 $45.1 Million - $56.1 Million	-3,276,499 Reduced 89.26%	394,169 $5.93 Million
Q4 2017 Feb 09, 2018	BUY	$12.51 - $16.24 $22.4 Million - $29.1 Million	1,794,110 Added 95.61%	3,670,668 $52.8 Million
Q3 2017 Nov 09, 2017	BUY	$11.74 - $15.78 $22 Million - $29.6 Million	1,876,558	1,876,558 $28.3 Million

Others Institutions Holding FOLD

# of Institutions

278

Shares Held

324M

Call Options Held

260K

Put Options Held

261K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $3.06B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account